GLSI News and Press, Greenwich LifeSciences Inc. From 07/12/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: arfa adam / Shutterstock.com Versus Systems (NASDAQ: VS ) stock is rising higher on Tuesday after getting a delisting warning from the Nasdaq Exchange about a month ago. That warning gives Versus S...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Greenwich Lifesciences (NASDAQ: GLSI ) stock is heading higher on Tuesday after the U.S. Food and Drug Administration (FDA) lifted a hold on a Phase III clinical trial . ...

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...

Greenwich LifeSciences ( NASDAQ: GLSI ) entered into an Open Market Sale Agreement with Jefferies as sales agent wherein it may issue and sell from time to time shares par value $0.001/ share. It may issue and sell stock having total offering price of up to $100M...

Histogen ( HSTO ) +78% . Canoo ( GOEV ) +74% after signing a deal with Walmart for 4,500 all electric delivery vehicles. Novo Integrated Sciences ( NVOS ) +14% expects to report over fivefold increase in Q3 revenue. Annexon ( ANNX ) +13% p...

Greenwich LifeSciences ( NASDAQ: GLSI ) said the U.S. Food and Drug Administration (FDA) removed a clinical hold on a phase 3 trial in breast cancer allowing it to progress. The trial, dubbed Flamingo-01 , will evaluate a combination of immunotherapy GP2 + GM-...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that the Food and Drug Administration (FDA) has removed the clinical hold permitting the Flamingo-01 Phase III clinical...

Greenwich LifeSciences ( NASDAQ: GLSI ) said Monday it suspended its share repurchase program. GLSI repurchased ~520K shares for ~$7.5M under the program, which had been resumed in May . The firm had ~12.8M shares outstanding following the buybacks. For furth...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program. Under...

The stock market has been under unimaginable selling pressure for the last several quarters. The stock market sell-off has been exasperated by the Fed's actions to reduce inflation. This lays out a vast buying opportunity that only the most skilled investors/traders will take adva...